The Effect of *Laminaria japonica* on Metabolic Syndrome: A Systematic Review of Its Efficacy and Mechanism of Action

In-Seon Lee 1,2,†, Seok-Jae Ko 3,†, Yu Na Lee 4, Gahyun Lee 4, Md. Hasanur Rahman 4 and Bonglee Kim 4,*

1 Department of Meridians and Acupoints, College of Korean Medicine, Kyung Hee University, Seoul 05253, Korea; inseon.lee@khu.ac.kr
2 Acupuncture & Meridian Science Research Center, Kyung Hee University, Seoul 02447, Korea
3 Department of Gastroenterology, College of Korean Medicine, Kyung Hee University, Seoul 05253, Korea; kokoko19@khu.ac.kr
4 College of Korean Medicine, Kyung Hee University, Seoul 05253, Korea; unaly@khu.ac.kr (Y.N.L.); dlrkgsil77@khu.ac.kr (G.L.); hasanurrahman.bge@gmail.com (M.H.R.)

* Correspondence: bongleekim@khu.ac.kr; Tel.: +82-2-961-9217
† These authors contributed equally to this work.

Abstract: Metabolic syndrome (MetS) is a medical condition characterized by abdominal obesity, insulin resistance, high blood pressure, and hyperlipidemia. An increase in the incidence of MetS provokes an escalation in health care costs and a downturn in quality of life. However, there is currently no cure for MetS, and the absence of immediate treatment for MetS has prompted the development of novel therapies. In accordance with recent studies, the brown seaweed *Laminaria japonica* (LJP) has anti-inflammatory and antioxidant properties, and so forth. LJP contains bioactive compounds used as food globally, and it has been used as a medicine in East Asian countries. We conducted a systematic review to examine whether LJP could potentially be a useful therapeutic drug for MetS. The following databases were searched from initiation to September 2021: PubMed, Web of Science, EMBASE, and Cochrane Central Register of Controlled Trials Library. Clinical trials and in vivo studies evaluating the effects of LJP on MetS were included. LJP reduces the oxidative stress-related lipid mechanisms, inflammatory cytokines and macrophage-related chemokines, muscle cell proliferation, and migration. Bioactive-glucosidase inhibitors reduce diabetic complications, a therapeutic target in obesity and type 2 diabetes. In obesity, LJP increases AMP-activated protein kinase and decreases acetyl-CoA carboxylase. Based on our findings, we suggest that LJP could treat MetS, as it has pharmacological effects on MetS.

Keywords: metabolic syndrome; *Laminaria japonica*; atherosclerosis; diabetes; obesity; AMPK

1. Introduction

Metabolic syndrome (MetS) is characterized by abdominal obesity, insulin resistance, hypertension, and hyperlipidemia [1]. Cancer, diabetes, atherosclerosis, obesity, and hyperlipidemia disrupt the metabolic balance and are associated with MetS, which is caused by impediments to anabolism and catabolism in the human body [2]. Hyperglycemia, hyperlipidemia, hyperinsulinemia, hypertension, and atherosclerosis are symptoms of diabetes mellitus (DM), a chronic metabolic condition that affects the body’s ability to process carbohydrates, lipids, and lipoproteins [3]. The increased consumption of high-calorie and low-fiber food and decreased physical activity result in a higher incidence of MetS, leading to high health care costs and poor quality of life [1]. In recent decades, the prevalence of MetS has reached an epidemic-level, with approximately 2 billion adults affected and 1/3 of children being obese; this is a significant public health and clinical concern worldwide [4,5]. However, there is currently no cure for MetS, but certain disciplined lifestyles and prescribed drugs could prevent the long-term effects of the disease. A broad
range of therapies has been approved by the United States Food and Drug Administration (FDA) that address the different biological systems and mechanisms implicated in this disease. There are 59 FDA-approved antihyperglycemic medicines that have been unique since the FDA approved human insulin in 1982. A total of 36 novel molecular entities (NMEs) as monotherapies and 23 unique pharmacological combinations of two or more antihyperglycemic medicines have also been licensed. NMEs, recently licensed as monotherapies, are based on molecular pathways that have been validated by other authorized antihyperglycemic medicines [6]. There is no guarantee of full recovery by the FDA-approved drugs for MetS, and they also have some long-term and short-term side effects including flatulence, abdominal bloating and discomfort, diarrhea, and an increase in bladder cancer [7]. Furthermore, non-selective drug resistance and bioavailability are some of the drawbacks of the conventional therapies for MetS [1]. Therefore, developing novel drugs for the treatment of MetS is urgently required.

Brown seaweed is an excellent source of carbohydrates, vital amino acids, vitamins, minerals, and other nutrients. According to recent studies, brown seaweed contains various phenolic compounds with anti-inflammatory, antioxidant, and anticarcinogenic properties [8]. Laminaria species are a vital marine medicinal food source that have biological effects on the human body [9], wherein Laminaria japonica (LJP) is a rich source of algae, minerals, and dietary fiber as well as a vital source of dietary fiber production [10]. In Korea, Japan, and China, LJP is cultured as one of the most economically important seaweeds [11]. It is a traditional food and medicine in Asia due to its pharmacological and biochemical qualities. It is also known as kelp, sea tangle, kombu or kunbu in Japan, and dashima in Korea [1].

According to recent studies, polysaccharides are the most crucial physiologically active components of LJP. Algin, laminarin, fucoidan, varying quantities of galactose, xylose, and glucuronic acid as well as a small amount of protein are the main components of the natural macromolecules found in the intercellular or intracellular layer of the LJP [3]. LJP has multiple pharmacological effects including anti-tumor, anti-thrombotic, anti-atherosclerosis, hypolipidemic, hypoglycemic, antioxidant, anti-inflammatory, renoprotective, and immunomodulatory [12]. In addition, LJP protects against several metabolic syndromes including diabetes, obesity, and atherosclerosis [3,13,14]. Some in vitro studies have also identified an antithrombotic effect in LJP [15]. However, there is no systematic review of studies testing for the effects of LJP on MetS, and we aimed to address the role of LJP on the treatment of MetS.

In this study, we conducted a systematic review to determine the effects and mechanisms of LJP in treating patients with MetS and the possibility of using LJP as a therapeutic drug. We also discuss the mechanisms to delve deeper into its molecular pharmacology and highlight the recent progression of its therapeutic developments. This review is expected to direct future research toward a better understanding of how LJP could modulate MetS and be developed as a potential therapeutic component for the treatment of MetS.

2. Materials and Methods

2.1. Search Strategy and Registration

A systematic review was conducted to retrieve and critically appraise the available evidence on the effects of LJP on MetS. The literature search was performed in September 2021 using four databases: PubMed, Web of Science, EMBASE, and the Cochrane Central Register of Controlled Trials Library. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to conduct the present systematic review [16]. Intervention-related terms such as ‘LJP’, ‘kelp’, ‘kombu’, ‘kunbu’, and disease-related terms ‘metabolic’, ‘cardiovascular’, ‘hypertension’, ‘glucose’, ‘diabetes’, ‘insulin resistance’, ‘cholesterol’, ‘obese’, etc., were used in the search. The search strategy for each database can be found in the Supplementary Table S1. This systematic review was registered in the Open Science Framework registry (https://osf.io/g2bqk, accessed on 5 September 2021) and the protocol has been previously published [1].
2.2. Eligibility Criteria

The eligibility criteria were based on the population (P), intervention (I), comparison (C), outcome (O), and study design (S) (PICOS) strategy. Clinical trials and in vivo studies that evaluated the effect of LJP on MetS including obesity, diabetes, hyperlipidemia, fatty liver, and atherosclerosis were included. We excluded duplicate articles, those that were not written in English, original studies, non-LJP-related studies, in vitro studies, or disease-related studies.

2.3. Data Extraction

The process of data extraction from the studies in this systematic review are summarized in Figure 1, providing the following information: author, year of publication, sample size, characterization of the study population, interventions, controls (if applicable), clinical outcomes, results, and adverse events (in clinical trials only).

Figure 1. The PRISMA flow diagram of the selection and inclusion process of the studies.

2.4. Quality Assessment and Risk of Bias

To ensure that the results of the evidence synthesis are transparent, the risk of bias assessment was performed for randomized controlled trials (RCT) using the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) for individually randomized RCTs [17]. RoB 2 for cross-over trials was used in the cross-over RCT study. Following the guidelines, we assessed each study’s risk of bias based on the randomization process, the deviations from the intended interventions, missing outcome data, outcome measurement, the selection of the reported result, and period and carry-over effects (only for the cross-over study). Cochrane Methods (https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials, accessed on 24 September 2021) offers an Excel
tool that we used to calculate the risk of bias and to generate a table of the assessment result.

2.5. Literature Search

Of the 727 studies found in the search (PubMed, $n = 145$; Web of Science, $n = 396$; EMBASE, $n = 168$; and Cochrane Central Register of Controlled Trials Library, $n = 18$), the titles and abstracts of 457 articles and the full texts of 73 articles were screened after removing any duplicates ($n = 270$). A total of 419 articles were excluded (not written in English, $n = 9$; not an original study, $n = 39$; not related to LJP, $n = 133$; an in vitro study, $n = 28$; and not related to MetS, $n = 212$). Finally, 36 articles (eight clinical trials and 28 in vivo studies) were included in the present systematic review (Figure 1).

2.6. Studies Characteristics

Of the 36 studies, eight evaluated the effect of LJP on MetS in humans. Of the remaining 28 animal studies, 10 evaluated the effect of LJP on diabetes, seven on obesity, eight on atherosclerosis, and three on hyperlipidemia/fatty liver. All clinical trials were conducted on healthy participants.

3. Results

3.1. Animal Studies

3.1.1. Diabetes

The anti-diabetic effects of LJP have been reported in 10 studies (Table 1). Jia et al. [3] reported that polysaccharides from LJP had hypoglycemic and hypolipidemic effects in mice with alloxan-induced diabetes. Twenty-eight days of LJP administration prevented body weight loss, decreased the glucose levels, and increased the insulin levels. It also ameliorated the alloxan-induced alterations in lipid metabolism.

Li et al. [18] demonstrated the hypoglycemic effect of LJP in a mouse model of type 2 DM. They suggested that LJP may partially recover the secretory function of islet cells, leading to improved regulation of glucose metabolism. Two weeks of oral LJP administration significantly reduced the fasting glucose levels and increased serum insulin and amylin levels in alloxan-induced DM mice.

Bu et al. [19] focused on the hypoglycemic effect of butyl-isobutyl-phthalate (BIP) as an active compound in the rhizoids of LJP, as determined by spectral analysis. BIP exhibited significant concentration-dependent inhibitory activity against $\alpha$-glucosidase in vitro. In vivo, three days of oral administration of BIP significantly reduced the blood glucose levels in streptozotocin (STZ)-induced diabetic mice.

Jin et al. [20] reported that pretreatment with 100 mg/kg aqueous LJP extract for 5 days reduced glucose levels, hepatic lipid peroxidation, and xanthine activity in diabetic rats. The LJP extract may scavenge the reactive oxygen species or enhance the utilization efficiency of glutathione, thereby reducing the lipid peroxidation levels in the liver of diabetic rats.

Liang et al. [21] demonstrated the protective effect of low-molecular-weight fucoidan (LMWF) from LJP on lipid profiles and basal blood pressure by ameliorating oxidative stress, prostanoid production, and hyper-responsiveness of aortic smooth muscles in STZ-induced rats with type 1 DM.

Park et al. [22] found that 13 weeks of oral administration of sea tangle (LJP) powder (15% w/w) or sea tangle water extract (4% w/w) decreased the blood glucose levels and improved lipid metabolism in STZ-induced diabetic rats. This effect might be exerted by increased serum insulin levels and fecal excretion of lipids, preventing lipid absorption.
Table 1. An overview of the included in vivo studies on the efficacy of LJP on diabetes.

| Animal Model   | Diabetes-Inducer | Positive Control | Active Compounds | Administration Route | Dosage       | Treatment Duration | Mechanisms                                                                 | Lab Test                                                                 | Efficacy                                      | References |
|----------------|------------------|------------------|------------------|----------------------|--------------|--------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------|------------|
| Kunming mice  | Alloxan          | Glibenclamide    | Polysaccharide   | Oral                 | 50, 100, 200 mg/kg | 28 days            | ↑ Glucose utilization, ↓ Hormone-sensitive lipase, free fatty acids mobilization | ↑ Insulin, HDL-C, ↓ FBG, TC, TG, LDL-C                                                 | Hypoglycemic, hypolipidemic effect             | [3]        |
| Kunming mice  | Alloxan          | None             | Polysaccharide   | Oral                 | 75, 150, 300 mg/mL | 2 weeks            | Recovery of the secretory function of islet cells                           | ↑ Insulin, amylin, ↓ FBG                                                                      | Hypoglycemic effect                           | [18]       |
| Kunming mice  | Streptozocin     | Ethyl acetate fraction, acarbose | Butylisobutylphthalate | Intragastric         | 25, 50, 100 mg/kg | 3 days             | ↓ α-glucosidase                                                              | ↓ Glucose                                                                 | Hypoglycemic effect                           | [19]       |
| Sprague-Dawley rats | Streptozocin | None             | NR               | Oral                 | 100 mg/kg       | 5 days             | ↑ Utilization efficiency of GSH, ↓ ROS                                       | ↑ GSH, GSH reductase, GSH peroxidase, XD, ↓ Glucose, XO                              | Anti-hyperglycemic, antioxidant effect        | [20]       |
| Sprague-Dawley rats | Streptozocin | Probucol         | Low molecular weight fucoidan | Intragastric         | 50, 100 mg/kg    | 12 weeks            | ↓ Oxidative stress, prostanoid production, hyper-responsiveness of aortic smooth muscles | ↑ GSH, SOD, 6-keto-PGF1α, ↓ BP, TC, TG, LDL-C, MF, COX-2 expression, TXAS | Hypolipidemic, hypotensive, antioxidant effect | [21]       |
| Sprague-Dawley rats | Streptozocin | None             | NR               | Ad libitum           | 4, 15% w/w      | 13 weeks           | ↑ Bile acid synthesis, lipid excretion, ↓ Lipid absorption                 | ↑ Insulin, fecal TC, fecal TG, ↓ Glucose, TC, TG, LDL-C, Hepatic TG                   | Hypoglycemic, Hypolipidemic effect             | [22]       |
| Wister rats   | Streptozocin     | PKC inhibitor    | Sulfated polysaccharide | Intragastric         | 200 mg/kg       | 80 days            | ↓ RI, Urinary volume, BUN, urinary protein/Cr, serum Cr, histopathological score, PKC-αPKC-β, NF-κB, p65, P-selectin | Downregulation of PKC, modulation of NF-κB signaling pathway | The effect of mitigating diabetic nephropathy | [23]       |
| Animal Model                  | Diabetes-Inducer | Positive Control | Active Compounds         | Administration Route | Dosage      | Treatment Duration | Mechanisms                                                   | Lab Test                                                                 | Efficacy                       | References |
|-------------------------------|------------------|------------------|--------------------------|----------------------|-------------|-------------------|-------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------|------------|
| Wister rats                   | Alloxan          | None             | NR                       | Oral                 | 1.25, 5.0, 12.5 g/kg | 2 weeks          | ↑ Anti-oxidation, Recovery of the pancreatic islet cell secreting function | ↑ Insulin, SOD, GSH-Px, B cell index, ↓ FBG, MDA, NO, pancreatic SOD, pancreatic iNOS | Hypoglycemic, antioxidant effect | [24]       |
| Type 2 diabetic Goto-Kakizaki rats | Sodium laurate  | Cilostazol       | Low molecular weight fucoidan | Intragastric         | 20, 40, 80 mg/kg   | 4 weeks          | ↑ VEGF expression, eNOS phosphorylation, NO production     | ↑ HDL-C, NO, plantar capillary density, neovascularization around femoral artery, gastrocnemius size, weight, ↓ TG, TG, LDL-C, ulceration score, claudication score, vascular plaques rate, intimal hyperplasia thickness, ICAM-1, IL-1β, ADP | Anti-inflammation, anti-thrombosis, enhancing revascularization effect | [25]       |
| C57BL/6N mice                 | High-fat diet    | None             | Total Polyphenol         | Oral                 | 5%          | 16 weeks         | Regulation of α-glucose homeostasis, ↑ muscle glucose uptake, activation of insulin-signaling-related proteins | ↑ IL-6, IL-10, p-Akt, p-AMPK, ↓ α-glucosidase activity, TNF-α | Antidiabetic effect | [8]        |

6-keto-PGF1α: a stable metabolite of prostaglandin I2; ADP: adenosine diphosphate; B cell index: the number of pancreatic islets B cells/total number of cells) × 100; BP: blood pressure; BUN: blood urea nitrogen; COX-2: cyclooxygenase-2; Cr: creatinine; eNOS: endothelial nitric oxide synthase; FBG: fasting blood glucose; FFA: free fatty acids; GSH: glutathione; GSH-Px: glutathione peroxidase; HDL-C: high-density lipoprotein-cholesterol; ICAM-1: intercellular adhesion molecule-1; IL: interleukin; iNOS: inducible nitric oxide synthase; LDL-C: low-density lipoprotein-cholesterol; LJP: *Laminaria japonica*; MDA: malondialdehyde; MP: maximum force generation of rings from endothelium-denuded thoracic aorta in response to the accumulated stimulation with phenylephrine; NF-κB: nuclear factor kappa B; NO: nitric oxide; NR: Not reported; p-Akt: phosphorylation of protein kinase B; p-AMPK: phosphorylation of α5′ adenosine monophosphate-activated protein kinase; PKC: protein kinase C; RI: renal index, renal weight × 100/body weight; ROS: reactive oxygen species; SOD: superoxide dismutase; TC: total cholesterol; TG: triglycerides; TL: total lipid; TNF-α: tumor necrosis factor-α; TXAS: thromboxane synthase; VEGF: vascular endothelial growth factor; XD: xanthine dehydrogenase; XO: xanthine oxidase. ↑: increased; ↓: decreased.
Xu et al. [23] investigated the effect of sulfated polysaccharides (SPS) extracted from LJP to relieve diabetic nephropathy (DN) in an STZ-induced diabetic model. The administration of gavage-fed SPS (200 mg/kg) for 80 days decreased the blood urea nitrogen, serum creatinine levels, and symptoms of DN. Changes in the expression of protein kinase C (PKC)α, PKCβ, P-selectin, nuclear factor kappa B (NFκB), and p65 showed that SPS regulates DN via the PKC/NF-κB pathway.

Long et al. [24] reported on the hypoglycemic effect of kelp (LJP) in alloxan-induced DM model rats. Two weeks of oral administration of kelp lowered the fasting blood glucose (FBG), malondialdehyde (MDA), and nitric oxide (NO). The shape and structure of the islet cells improved with the upregulation of superoxide dismutase (SOD) and the downregulation of inducible nitric oxide synthase (iNOS) in the kelp-treated group. Kelp might help recover the secreting function of islet cells and decrease the level of FBG through its antioxidiant effect.

Wang et al. [25] investigated the anti-inflammatory, anti-thrombosis, and revascularization effects of LJP extracts from LJP in diabetic peripheral arterial disease rats. LMWF exhibited a therapeutic effect on hindlimb ischemia in diabetic rats, likely by ameliorating the dysfunction of endothelial NOS and enhancing revascularization.

Kang et al. [8] investigated the antidiabetic effect and possible mechanism of LJP using in vitro and high-fed diet in vivo models. Sixteen weeks of oral administration of LJP induced insulin-signaling-related proteins such as the phosphorylation of protein kinase B in the skeletal muscle. LJP also affects glucose homeostasis by inhibiting α-glucosidase activity, increasing muscle glucose uptake, and regulating inflammatory cytokines in the skeletal muscle cells (Figure 2).

**Figure 2.** Schematic overview of main mechanisms of *Laminaria japonica* (LJP) against diabetes. Insulin resistance with impairment of insulin signaling, hyperinsulinemia, and hyperglycemia contributes to multiple processes including elevated free fatty acids (FFA), protein kinase C (PKC) activation, and oxidative stress, contributing to inflammation and endothelial dysfunction simultaneously. LJP may decrease the mobilization of FFA and oxidative stress, the downregulation of PKC, and the modulation of inflammatory mediators including tumor necrosis factor-α (TNF-α) and interleukins, and the nuclear factor kappa B (NF-κB) signaling pathway. Meanwhile, α-glucosidases are glycoside hydrolases found on the luminal surface of enterocytes containing maltase activities. LJP can help regulate and maintain an adequate blood sugar level by inhibiting α-glucosidase. LJP also has the potential to increase glucose uptake and responsiveness to insulin in the muscle and recover the pancreatic islet cell secreting function. FFA: free fatty acids; LJP: *Laminaria japonica*; NF-κB: nuclear factor kappa B; PKC: protein kinase C; TNF-α: tumor necrosis factor-α; ↑: increased; ↓: decreased.
3.1.2. Obesity

Seven studies reported the anti-obesity effects of LJP (Table 2). Oh et al. [13] reported that LJP had anti-obesity and anti-inflammatory effects in high-fat diet (HFD)-fed mice. The treatment was continued for 16 weeks, and the LJP was supplemented with 5% of the diet. LJP reduces blood glucose, leptin, and circulating cytokine levels.

Shang et al. reported that fucoidan in LJP had a beneficial effect on diet-induced MetS in HFD-fed mice [26]. In the 16-week experiment, 200 mg/kg of LJP was orally administered to mice. Fucoidan reduced the levels of total cholesterol (TC), triacylglycerides (TAG), and fasting blood glucose.

Jang and Choung reported that the ethanol extract of LJP had an anti-obesity effect in HFD-fed mice [27]. According to the study, the extract reduced the levels of serum triglyceride (TG), TC, and low-density lipoprotein cholesterol (LDL-C). It increased the high-density lipoprotein cholesterol (HDL-C), HDL-C/TC ratio, and adiponectin. It also increased the ratios of p-AMPK/AMPK and p-ACC/ACC.

Zhang et al. reported that the insoluble dietary fiber of LJP improved the obesity-related features in HFD-fed mice and played a role in gut microbiota dysbiosis and protection against HFD-induced liver injury [28]. It was shown that fiber reduced the levels of serum glucose, TC, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) and restored the levels of acetate, propionate, and cecal short-chain fatty acid (SCFA).

Li et al. reported that polysaccharides from LJP could combat obesity by increasing p-AMPK and lowering the fatty acid synthase (FAS) and tumor necrosis factor (TNF)-α levels [29]. According to the experiment, high-fat mice administered with LJP polysaccharides experienced hypoglycemic effects, improved serum lipid profiles, and ameliorated intestinal damage.

Duan et al. reported that polysaccharides from LJP had an anti-obesity effect and normalized gut microbiota in HFD-fed mice [30]. In the experiment, 0.25% LJP solution was administered to mice as drinking water. LJP increases the HDL-C/LDL-C ratio and reduces the serum lipid levels.

Han et al. reported that LJP exerted a hypotriglyceridemic effect on HFD-fed mice by phosphorylating 5 AMP-activated protein kinase [31]. LJP was supplemented with 5% of the diet during the 16-week experiment. According to this study, LJP increased the fecal bile acid and reduced the FBG levels, plasma triglyceride levels, and hepatic lipid accumulation (Figure 3).
| Animal Model       | Obesity-Inducer | Active Compounds | Administration Route | Dosage          | Treatment Duration | Positive Control | Mechanisms                          | Lab Test                                                        | Efficacy                        | Reference |
|-------------------|-----------------|-----------------|---------------------|-----------------|-------------------|-----------------|-----------------------------|---------------------------------------------------------------|----------------------------------|-----------|
| C57BL/6N mice     | HFD             | N/A             | Oral supplementing 5% of the diet | 16 weeks       | None              | ↓ IL-1β, IL-6    | ↓ blood glucose, leptin     | Anti-obesity effect Anti-inflammatory effect | [13]                |           |
| C57BL/6J mice     | HFD             | Fucoidan        | Oral                | 200 mg/kg       | 16 weeks          | None            | ↓ TNF-α, IL-1β, MCP-1      | ↓ TC, TAG, fasting blood glucose, serum LBP | Beneficial effect on MetS        | [26]        |
| SD rats           | HFD             | Ethanol extract | Oral                | 400 mg/kg       | 6 weeks           | None            | ↑ p-AMPK/AMPK, p-ACC/ACC, ↓ TNF-α | ↓ serum glucose, TC, HDL-C, LDL-C, FFA, leptin, insulin ↑ HDL-C and LDL-C/TC ratio, adiponectin | Anti-obesity effect              | [27]        |
| C57BL/6 mice      | HFD             | Insoluble dietary fiber | Oral supplementing 5% of the diet | 8 weeks       | None              | ↑ p-AMPK/AMPK, ↓ FAS, TNF-α | ↑ regulation of SREBP-1c/FAS signaling | ↑ adiponectin secretion ↓ TG, TC, FFA, leptin secretion, Hepatic TG, cholesterol content in the liver, serum LDL-C | Hypoglycemic effect, improved serum lipid profiles, ameliorated intestinal damage | [28]        |
| C57BL/6J mice     | HFD             | Polysaccharide  | Oral                | HFD plus 2 g/kg SP | 8 weeks           | None            | ↑ p-AMPK/AMPK, ↓ FAS, TNF-α | ↑ ratio of HDL-C/LDL-C, SCFAs ↓ levels of serum lipids, | Gut microbiota normalization Anti-obesity effect | [29]        |
| BALB/c mice       | high-fat diet   | Polysaccharide  | Oral                | 0.25% LJPs solution as drinking water | 10 weeks (not specified) | None              | ↑ Fecal BA ↓ Fasting blood glucose levels, Plasma TG levels, hepatic lipid accumulation | Gut microbiota normalization | Anti-obesity effect | [30]        |
| C57BL/6N mice     | High-fat diet   | N/A             | Oral                | supplementing 5% of the diet | 16 weeks       | None              | ↑ p-AMPK/AMPK, ↓ FAS, TNF-α | ↑ ratio of HDL-C/LDL-C, SCFAs ↓ levels of serum lipids, | Hypotriglyceridemic effect | [31]        |

ACC: acetyl-CoA carboxylase; ALT: alanine aminotransferase; AMPK: AMP-activated protein kinase; AST: aspartate aminotransferase; FAS: fatty acid synthase; FFA: free fatty acid; HDL-C: high-density lipoprotein cholesterol; HFD: high-fat diet; LBP: lipopolysaccharide-binding protein; LDL-C: low-density lipoprotein-cholesterol; MetS: diet-induced metabolic syndrome; N/A: not available; SCFA: short-chain fatty acid; SP: seaweed low-molecular-weight polysaccharide; SREBP: sterol regulatory element-binding protein-1; TAG: triglyceride; ↑: increased; ↓: decreased.
Shang et al. reported that fucoidan in LJP had a beneficial effect on diet-induced MetS in HFD-fed mice [26]. In the 16-week experiment, 200 mg/kg of LJP was orally administered to mice. Fucoidan reduced the levels of total cholesterol (TC), triacylglycerides (TAG), and fasting blood glucose.

Jang and Choung reported that the ethanol extract of LJP had an anti-obesity effect in HFD-fed mice [27]. According to the study, the extract reduced the levels of serum triglyceride (TG), TC, and low-density lipoprotein cholesterol (LDL-C). It increased the high-density lipoprotein cholesterol (HDL-C), HDL-C/TC ratio, and adiponectin. It also increased the ratios of p-AMPK/AMPK and p-ACC/ACC.

Zhang et al. reported that the insoluble dietary fiber of LJP improved the obesity-related features in HFD-fed mice and played a role in gut microbiota dysbiosis and protection against HFD-induced liver injury [28]. It was shown that fiber reduced the levels of serum glucose, TC, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) and restored the levels of acetate, propionate, and cecal short-chain fatty acid (SCFA).

Li et al. reported that polysaccharides from LJP could combat obesity by increasing p-AMPK and lowering the fatty acid synthase (FAS) and tumor necrosis factor (TNF)-α levels [29]. According to the experiment, high-fat mice administered with LJP polysaccharides experienced hypoglycemic effects, improved serum lipid profiles, and ameliorated intestinal damage.

Duan et al. reported that polysaccharides from LJP had an anti-obesity effect and normalized gut microbiota in HFD-fed mice [30]. In the experiment, 0.25% LJP solution was administered to mice as drinking water. LJP increases the HDL-C/LDL-C ratio and reduces the serum lipid levels.

Han et al. reported that LJP exerted a hypotriglyceridemic effect on HFD-fed mice by phosphorylating 5 AMP-activated protein kinase [31]. LJP was supplemented with 5% of the diet during the 16-week experiment. According to this study, LJP increased the fecal bile acid and reduced the FBG levels, plasma triglyceride levels, and hepatic lipid accumulation (Figure 3).

Figure 3. A schematic overview of the principal mechanisms of LJP against obesity. In normal conditions, AMPK upregulates fatty acid oxidation by inhibiting ACC and downregulates FA synthesis by inhibiting the dephosphorylation of transcription factor SREBP-1c. Additionally, obesity inhibits the AMPK, increasing the FA synthesis and reducing FA oxidation. LJP reversed the obesity-induced FA synthesis and increased the AMPK activity and FA oxidation. ACC: acetyl coenzyme A carboxylase, AMPK: AMP-activated protein kinase, CPT-1: carnitine palmitoyl transferase 1, FAS: fatty acid synthase, SREBP-1c: sterol regulatory element-binding protein 1c.

3.1.3. Atherosclerosis

Eight studies elucidated the anti-atherosclerotic effects of LJP (Table 3). Most studies used mouse models with dietary interventions (high-fat, high cholesterol, and hyperlipidemia) to induce atherosclerosis. Yao et al. reported that a kelp extract obtained with citric acid instead of water significantly lowered the possibility of atherosclerosis by ABTS (2,2′-Azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) radical scavenging activity [14]. According to the experiment, high-fat mice administered the LJP citric acid extract experienced hypolipidemic and antioxidative effects and decreased the incidence of cardiovascular and cerebrovascular disease.
Table 3. An overview of the included in vivo studies on the efficacy of LJP on atherosclerosis.

| Animal Model       | Atherosclerosis Inducer | Active Compounds | Administration Route | Dosage                  | Treatment Duration | Positive Control | Mechanisms                                                                                                                | Lab Test                                      | Efficacy                                                                                       | Reference |
|--------------------|-------------------------|------------------|----------------------|-------------------------|--------------------|------------------|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------|-----------|
| Guangdong mice     | ROS/RNS                 | Polysaccharide   | Oral                 | 200 mg/kg/body mass/day | 4 weeks            | None             | ↑ ABTS, ↓ TC, HDL-C, TG, LDL-C/HDL-C ratio                                                                                 |                                               | Anti-cardiovascular diseases, hypolipidemic, antioxidative effects | [14]      |
| C57BL/6 mice       | HFD                     | Polysaccharide   | Oral                 | 200 mg/kg/body mass/day | 8 weeks            | None             | ↑ intestinal goblet cells, ↓ ACC1, PPAR-γ, TNF-α, MAPKs, p-ERK, p-JNK, Akkermansia, ↓ glyceria, glucose, MAPKs, p-ERK, p-JNK, Akkermansia | ↑ SOD, ↓ SOD, ↓ ACC1, ↓ TNF-α, ↓ MAPKs, ↑ SOD | Anti-insulin resistance, anti-obesity, anti-inflammation effects | [32]      |
| LDLr−/− mice       | HFD                     | Polysaccharide   | Oral                 | 200 mg/kg/body mass/day | 14 weeks           | None             | ↑ SOD, ↓ MAPKs, TNF-α, p-ERK1/2, p-JNK1/2, ↓ atherosclerotic plaque, TC, TG, LDL-C/HDL-C, MDA                        | ↑ SOD, ↓ SOD, ↓ MAPKs, ↑ HDL-C, ↑ HDL-C, ↑ HDL-C | Anti-atherosclerotic, hypolipidemic, antioxidative effects                                           | [33]      |
| Sprague-Dawley rats| HFD                     | FPS              | Oral                 | 0.4 g/kg                | 8 weeks            | None             | ↑ LPL, LCAT, ↓ TD, ↓ LDL-C, ↓ synthesis of endogenous lipids                                                              | ↑ LPL, LCAT                                   | Hypoglycemic, anti-atherosclerotic cardiovascular diseases effects                              | [34]      |
| BALB/c mice        | HFD                     | L-LJA            | Oral                 | 0.3%                    | 11 weeks           | None             | ↑ GPR41, GPR43, ↓ PPAR-γ, ↑ SOD, ↓ HDL-C, ↓ SOD, ↓ CAT, ↓ LDL-C, ↓ synthesis of endogenous lipids                         | ↑ GPR41, ↑ SOD, ↓ PPAR-γ, ↓ PPAR-γ, ↓ SOD | Anti-obesity effect                                                                                                           | [35]      |
| Kunming mice       | Hyperlipidemic diets    | Polysaccharides  | Oral                 | 100, 200, 400 mg/kg/day| 12 weeks           | None             | ↑ SOD, CAT, GST, ↓ TG, ↓ HDL-C, ↓ LDL-C, SOD, ↓ HDL-C, ↓ LDL-C, ↓ synthesis of endogenous lipids                         | ↑ GPR41, ↑ SOD, ↓ PPAR-γ, ↓ PPAR-γ, ↑ HDL-C | Hypolipidemic, enhancing antioxidant enzyme effects                                            | [36]      |
| LDL receptor-deficient C57BL/6 mice | HCD                   | Polysaccharide (Fucoidan) | Oral                 | 50, 100 mg/kg/day | 16 weeks           | None             | ↓ LOX-1, IL-1b, IL-6, TNF-α, ICAM-1, VCAM-1, ↓ TG, ↓ HDL-C, ↓ LDL-C, ↓ atherosclerotic plaque formation, macrophage infiltration, smooth muscle cell proliferation, ROS generation | ↓ LOX-1, IL-1b, IL-6, TNF-α, ICAM-1, VCAM-1 | Anti-atherosclerotic, hypolipidemic, anti-inflammatory effects                                     | [37]      |
| Animal Model | Atherosclerosis Inducer | Active Compounds | Administration Route | Dosage       | Treatment Duration | Positive Control | Mechanisms                                                                 | Lab Test                                                                 | Efficacy                                    | Reference |
|--------------|------------------------|------------------|---------------------|-------------|-------------------|-----------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------|
| LDL receptor-deficient C57BL6J mice | HCD | Polysaccharide (Fucoidan) | Oral | 50, 100 mg/kg/day | 14 weeks | Simvastatin (5 mg/kg/day) | ↓ VLDL, SREBP-1c, ACC1, FAS, p-IRS-1, p-IRS-2, PI3K, AKT, P70S6K, nuclear Foxo1 | Anti-atherosclerotic, hypolipidemic, insulin signaling regulating effects | [38] |

ABTS: 2-2′-azinobis-(3-ethylbenzthiazoline-6-sulfonate); ACC1: Acetyl-CoA carboxylase; AKT: Protein kinase B; CAT: catalase; CE: cholesteryl ester; CPT-1A: carnitine palmitoyltransferase-1A; FAS: fatty acid synthase; FC: free cholesterol; FFA: free fatty acid; Foxo1: forkhead box protein O1; GPR: G protein-coupled receptor; GST: glutathione S transferase; HCD: high-cholesterol diet; HDL-C: high-density lipoprotein-cholesterol; HFD: High-fat diet; HOMA-IR: homeostasis model assessment of insulin resistance; ICAM-1: intercellular adhesion molecule-1; IL: interleukin; IRS: Insulin receptor substrate; JNK: c-Jun N-terminal kinase; LCAT: lecithin cholesterol acyltransferase; LDL-C: low-density lipoprotein-cholesterol; L-LJA: low- molecular alginate from *Laminaria japonica*; LOX-1: lectin-like oxidized low-density lipoprotein receptor-1; LPL: lipoprotein lipase; LPS: lipopolysaccharide; MAPKs: mitogen-activated protein kinases; MDA: malonaldehyde; ORAC: oxygen radical absorbance capacity; (p-)ERK: (phosphorylated) extracellular signal-regulated kinase; PI3K: phosphoinositide 3-kinase; PPAR-γ: peroxisome proliferator-activated receptors-γ; RNS: reactive nitrogen species; ROS: reactive oxygen species; SCFA: short chain fatty acids; SD: Sprague-Dawley; SOD: superoxide dismutase; SREBP-1c: sterol regulatory element-binding protein 1; TC: total cholesterol; TG: triglycerides; TNF-α: tumor necrosis factor α; VCAM-1: vascular cell adhesion molecule-1; VLDL: very low density lipoprotein; ↑: increased; ↓: decreased.
Li et al. reported that LJP polysaccharides can combat atherosclerosis by lowering various enzymes and receptors in the serum [32]. Furthermore, the study elucidated a causal relationship between LJP and enhanced insulin resistance by explaining the increased number of intestinal goblet cells and decreased Akkermansia in the serum of high-fat mice after ingesting LJP. In a mouse model in which a high-fat cholesterol diet produced atherosclerosis, Zha et al. examined the anti-atherosclerotic effect [38]. They discovered that 14 weeks of oral administration of polysaccharides derived from LJP (50 and 200 mg/kg/day) had significant hypolipidemic and anti-atherosclerotic benefits by modulating the hepatic insulin signaling system.

Peng et al. reported that LJP polysaccharides could combat atherosclerosis by increasing the number of SOD, thus inhibiting the phosphorylation of various enzymes and decreasing the amount of TNF [33]. According to this experiment, high-fat mice could undergo anti-atherosclerotic, hypolipidemic, and antioxidative effects.

Huang et al. reported that LJP polysaccharides could combat atherosclerosis by increasing the number of lipoprotein lipases and accelerating lecithin cholesterol acyltransferase activity [34]. According to the experiment, high-fat mice experienced hypoglycemic and anti-atherosclerotic effects of cardiovascular disease after ingesting LJP for 8 weeks.

Zheng et al. reported that LJP polysaccharides could combat atherosclerosis by increasing the number of G protein-coupled receptors and carnitine palmitoyltransferase-1A (CPT-1A) [35]. Simultaneously, peroxisome proliferator-activated receptor-γ (PPAR-γ) and TNF-α were downregulated, which ensured enhanced anti-obesity effects.

Zha et al. investigated the effects of LJP polysaccharides at a dose of 400 mg/kg/day [36]. The total serum TC, TG, high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) levels were reduced, while the antioxidant enzyme activities were increased.

Wang et al. studied the anti-atherosclerotic, hypolipidemic, and anti-inflammatory effects of fucoidan derived from LJP in a mouse model of high-cholesterol diet-induced atherosclerosis [37]. They discovered that either 50 mg/kg/day or 100 mg/kg/day of fucoidan for 16 weeks lowered the serum lipid levels (TG, TC, LDL-C, HDL-C), atherosclerotic plaque growth, lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) expression, and pro-inflammatory mediator expression (e.g., interleukin-6, TNF-α, intercellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) (Figure 4).

Figure 4. A schematic overview of the main mechanisms of LJP against atherosclerosis. Endothelial dysfunction causes lipid retention in the intima, the induction of endothelial expression of adhesion molecules, and the secretion of chemotactic substances, promoting leukocyte recruitment, adhesion, and
transmigration into the vessel wall in patients with atherosclerosis. VSMC migrates from the media into the intima after dedifferentiating from a contractile to a proliferating phenotype. LJP inhibits atherothrombosis by interrupting oxidative stress-related lipid peroxidation and the PI3K/Akt signaling pathway, promoting cell growth, proliferation, and angiogenesis. It also regulates inflammatory and macrophage-related cytokines IL-6, IL-1β, and TNF-α. LJP treats atherosclerosis through its inhibitory action on the enhanced proliferation and migration of VSMC in atherosclerosis patients.

ACC1: acetyl-CoA carboxylase; CAT: catalase; ICAM-1: intercellular adhesion molecule-1; IL: interleukin; LJP: Laminaria japonica; LOX-1: lectin-like oxidized low-density lipoprotein receptor-1; LPL: lipoprotein lipase; MAPKs: mitogen-activated protein kinases; MCP-1: monocyte chemoattractant proteins; (p-)ERK: (phosphorylated); PI3K/Akt: phosphoinositide 3-kinase/protein kinase B; PPAR-γ: peroxisome proliferator-activated receptors-γ; ROS: reactive oxygen species; SOD: superoxide dismutase; TNF-α: tumor necrosis factor-α; VCAM-1: vascular cell adhesion molecule-1; VSMC: vascular smooth muscle cells.

3.1.4. Hyperlipidemia/Fatty Liver

Two studies of anti-hyperlipidemia and fatty liver effects of LJP were reposted (Table 4). Zhang et al. (2020) reported that macroalgae LJP (MLJ) was a potential treatment for hyperlipidemia as high-fat mice were able to undergo hypolipidemic effects after being administered with MLJ [39]. The mechanism underlying this efficacy was increased SOD and glutathione peroxidase (GSH-Px).

Zhang et al. reported that Lactobacillus brevis FZU0713-fermented LJP (FLJ) had a beneficial effect in hyperlipidemic rats [40]. According to a previous study, the oral administration of FLJ regulated hepatic mRNA levels of the gene, thereby reducing the serum levels of TC and TG and increasing the fecal levels of acid acetate, propionate, and isobutyrate.

A dieckol-enriched extract of LPJ was found in a HFD-induced non-alcoholic fatty liver disease mouse model, which had a substantial hypolipidemic impact [41]. They discovered that taking 5 mg/kg of polyphenols orally for four weeks decreased the visceral fat index, plasma and hepatic lipid levels (TG, TC, HDL, LDL), and hepatic steatosis.
Table 4. An overview of the included in vivo studies on the efficacy of LJP on hyperlipidemia.

| Animal Model | Obesity-Inducer          | Active Compounds | Administration Route | Dosage       | Treatment Duration | Positive Control | Mechanisms                                      | Lab Test                  | Efficacy               | Reference |
|--------------|--------------------------|------------------|----------------------|--------------|-------------------|------------------|------------------------------------------------|--------------------------|------------------------|-----------|
| SD rats      | HFD                      | N/A              | Oral                 | 2.5 g/kg     | 8 weeks           | None             | ↑ SOD, GSH-Px, ↓ TG, TC, NEFA                   | ↓ HMGCR, SREBP-1c, CD36  | Hypolipidemic effect | [39]      |
| SPF male rats| HFD                      | N/A              | Oral                 | 1.0 mL       | 8 weeks           | None             | ↓ HMGCR, SREBP-1c, CD36, ↓ serum TC, TG, NEFA ↑ fecal acid acetate, propionate, isobutyrate | Anti-hyperlipidemia effect | [40]       |
| ICR mice     | Non-alcoholic fatty liver/high fat-diet | None | Oral                 | 50 mg/kg     | 4 weeks           | None             | ↑ AMPK and regulation of its downstream proteins ↑ p-AMPK, PPAR-α, APT-1, ↓ body weight, liver index, visceral fat index, plasma, and hepatic TC, TG, HDL, LDL, hepatic steatosis, accumulation of hepatic lipids, hepatocellular swelling, vacuoles (normal diet + LJP group) | Hypolipidemic effect | [41]       |

GSH-Px: glutathione peroxidase; NEFA: non-esterified fatty acids; SD: Sprague-Dawley; SOD: superoxide dismutase; TC: total cholesterol; TG: triglycerides; ↑: increased; ↓: decreased.
3.2. Clinical Studies

Four clinical trials evaluated the effects of LJP on the body fat and fat-related parameters (Table 5). You et al. evaluated the effect of a body weight control program that included 20 g of LJP per day [42]. They discovered that consuming LJP lowered the body weight, fat mass, waist–hip ratio, and body mass index and improved the quality of life and physical functioning. The results should be interpreted with caution because the program incorporated exercise and nutrition education, and the decrease in blood cholesterol levels was insignificant. Nishimura et al. conducted a clinical study to support the effect of LJP on body fat, gastrointestinal symptoms, and blood measurements [43]. They found that dried young LJP powder improved gastrointestinal symptoms including decreased passage of stools. The lipid profile did not improve, although it lowered body fat and serum triglyceride levels (in those with excessively high serum triglyceride levels). Nishiumi et al. studied serum lipid and molecular profiles in participants with excessively high serum triglyceride levels before and after consuming LJP [44]. They found that roasted LJP ameliorated gastrointestinal symptoms; an example is the decreased passage of stools. It reduced the body fat and serum triglyceride levels only in patients with excessively high serum triglyceride levels. They reanalyzed the data [45] and found that phosphatidylcholines with diacyl links, lysophosphatidylcholine/diethanolamine with acyl linkages, and free fatty acids were improved after LJP use. Aoe et al. conducted a double-blind clinical trial employing iodine-reduced powder of LJP and found that it significantly reduced the body fat percentage without affecting thyroid function [46].

Kang et al. studied the antioxidant effects of fermented LJP in participants with high gamma-glutamyl transferase (GGT) levels [47]. Consumption of fermented LJP for four weeks decreased the serum levels of GGT and malondialdehyde while increasing the catalase (CAT) and SOD activities. These findings suggest that fermented LJP possesses antioxidant and hypolipidemic properties. The effect of LJP on gut microbiota in healthy participants was explored by Ko et al. [48]. However, no significant changes in the number of microbiomes, gastrointestinal symptoms, bowel function, or quality of life were observed. Only those who received LJP paired with probiotics (lactic acid bacteria) experienced significant alterations in their microbiome.

Choi et al. investigated the effects of FLJ on brain-derived neurotrophic factor-related muscle growth, lipolysis, and total lean mass in middle-aged female participants. They found that 8 weeks of LJP consumption significantly decreased the total fat mass and triglycerides in body composition as well as significantly increased the serum brain-derived neurotrophic factor (BDNF), angiotensin-converting enzyme, human growth hormone, insulin-like growth factor-1 levels, and total lean mass as well as improvements in the total work, knee extension, and flexion, implying that LJP may have anti-obesity properties and increase the release of muscle-related growth hormones [49].
Table 5. An overview of the included clinical trials on the efficacy of LJP on metabolic syndrome.

| Patient /Inclusion Criteria                  | Intervention (n)                                      | Control (n)                     | Treatment Period | Outcome                                                                 | Main Results                                                                 | Adverse Effect | Reference/Research Design |
|---------------------------------------------|------------------------------------------------------|--------------------------------|------------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------------|----------------|--------------------------|
| Healthy, female (n = 22) /NR                 | Sea tangle (20 g/day)                                | -                              | 8 weeks          | Body composition, dietary intakes, QOL                                 | ↓ body weight/fat, BMI, intake of energy/protein/fat ↑ balanced diet/mealtime, intake of fiber improvement: QOL | NR             | [42]/CT                  |
| Healthy, high GGT/aged 25–60 year            | Fermented sea tangle (250 mg × 6)                    | Placebo                        | 4 weeks          | Oxidative stress                                                        | ↓ GGT, MDA ↑ SOD, CAT activities                                                 | No             | [47]/RCT                  |
| Healthy (n = 40) /aged 18–75 year            | LJP (625 mg)                                         | LJP + probiotics (lactic acid bacteria) | 4 weeks (+2 weeks follow-up) | Gastrointestinal symptom, QOL, microbiome                               | No significant changes                                                          | No             | [48]/RCT                  |
| Healthy, female (n = 21) /middle aged        | γ-aminobutyric acid-enriched fermented sea tangle (1000 mg/day) | Placebo (sucrose)              | 8 weeks          | Body composition, muscular strength                                      | ↑ fat, TG ↑ BDNF, ACE, HGH, IGF-1, total lean mass improvement: total work, muscle strength | No             | [50]/RCT                  |
| Healthy (n = 70) /LDL-C 120~160 mg/dL, BMI 22~30 | Dried kombu powder (2.0 g/day)                        | Placebo (dextrin powder)        | 6 weeks          | Liver/renal function, body composition, lipid/glucose profiles          | ↓ fat ↓ serum triglyceride (only in subjects with high serum triglyceride levels) ↑ TC, CPR, abdominal distension | No             | [43]/RCT                  |
| Healthy (n = 48) /NR                         | Roasted kombu (6 g/day)                              | -                              | 4 weeks          | Liver/renal function, lipid/glucose profiles, insulin, gastrointestinal symptoms | ↓ UA                                                                                     | No             | [44]/RCT, cross-over      |
| 1) Healthy (n = 48) 2) high TG (n = 9)       | Roasted kombu (6 g/day, first 4 weeks)                | Roasted kombu (6 g/day, last 4 weeks) | 4 weeks          | Lipid metabolomics                                                      | ↑ Plasmanyl/plasmenyl forms of PC, PE ↓ LPC, LPE improvement: PC/PE with DL, LPC/LPE with AL, FFA (high TG subjects) | NR             | [45]/RCT, cross-over (re-analysis) |
| Healthy (n = 50) /BMI < 30 kg/m²              | iodine-reduced boiled kelp powder (3 g alginate/day)  | Placebo                        | 8 weeks          | Lipids, thyroid hormone                                                | ↓ body fat (male subjects)                                                       | No             | [46]/RCT                  |

ACE: angiotensin converting enzyme; AL: acyl linkages; BDNF: brain-derived neurotrophic factor; BMI: body mass index; CAT: catalase; CPR: C-peptide immunoreactivity; CT: controlled clinical trials; DL: diacyl linkages; FFA: free fatty acid; GGT: gamma-glutamyl transferase/transpeptidase; GPx: glutathione peroxidase; GTP: γ-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; HGH: human growth hormone; Ht: hematocrit; IGF: insulin-like growth factor; IL: interleukin; LDH: lactate dehydrogenase; LDL-C: low-density lipoprotein cholesterol; LJP: Laminaria japonica; LPC: lysophosphatidylcholines; LPE: lysophosphatidylethanolamine; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; MCV: mean corpuscular volume; MDA: malondialdehyde; NR: not reported; PC: phosphatidylcholines; PE: phosphatidylethanolamines; QOL: quality of life; RCT: randomized controlled clinical trials; RBC: red blood cell; SOD: superoxide dismutase; TC: total cholesterol; TG: triglyceride; WBC: white blood cell; UA: uric acid; y: year(s); γ-GTP: γ-glutamyl transpeptidase; 1,5-AG: 1,5-anhydroglucitol.
3.3. Quality and Risk of Bias

The rating of most studies resulted in “some concerns”, and one cross-over RCT was found to have a “high risk” of bias, as the carryover effect was not controlled (no wash-out period). Most studies did not incorporate detailed information on the randomization, blinding, and allocation concealment; outcome assessor blinding was poorly reported (Table 6).

Table 6. The risk of bias assessment for the randomized clinical trials using the ROB 2 criteria.

| Author, Year / Research Design | Randomization Process | Deviations from Intended Interventions | Missing Outcome Data | Measurement of the Outcome | Selection of the Reported Result | Period & Carryover Effects | Overall |
|-------------------------------|-----------------------|---------------------------------------|----------------------|-----------------------------|---------------------------------|--------------------------|---------|
| [47]/RCT                      |                       | ●                                    | ●                    | ●                           | ●                               | -                        | ●       |
| [48]/RCT                      |                       | ●                                    | ●                    | ●                           | ●                               | -                        | ●       |
| [50]/RCT                      |                       | ●                                    | ●                    | ●                           | ●                               | -                        | ●       |
| [43]/RCT                      |                       | ●                                    | ●                    | ●                           | ●                               | -                        | ●       |
| [46]/RCT                      |                       | ●                                    | ●                    | ●                           | ●                               | -                        | ●       |
| * [44]/RCT, cross-over        | ●                     | ●                                    | ●                    | ●                           | -                               | ●                        | ●       |

* RoB 2 for cross-over RCT was used for this study. Cross symbols: high risk of bias; triangle symbols: some concerns; circle symbols: low risk of bias.

4. Discussion

MetS includes hypertension, abdominal obesity, hyperlipidemia, and insulin resistance [49]. Impaired metabolic homeostasis in the human body is the leading cause of this syndrome [2]. In this systematic review, we found that LJP could significantly improve the clinical outcomes in patients suffering from MetS and the laboratory measurements in in vivo models of MetS.

Several reviews have reported algae’s effects on lifestyle-related diseases including LJP. Shirosaki and Koyama introduced studies on the ability of LJP to prevent obesity and diabetes and some approaches for effective of the bioactivities found in LJP [9]. They showed that the potential usefulness of LJP as a functional food may be increased through different processing methods and the growth stage of LJP. They also conducted an in vitro study using Caco-2 cells and reported that LJP suppressed the transmission of glucose in monolayer membranes by inhibiting GLUT2, leading to decreased postprandial blood glucose levels. D’Orazio et al. showed that fucoxanthin (FX), a characteristic carotenoid present in brown seaweeds, and LJP had antidiabetic, anticancer, antioxidant, and anti-photoaging properties against lifestyle-related diseases [51]. Gabbia et al. demonstrated that various types of brown seaweeds could be used as a nutraceutical and functional food for treating MetS comorbidities [52]. The review suggested using seaweeds in young people and coeliac patients to supplement metabolic comorbidities. Popović-Djordjević et al. reported that bioactive compounds of algae such as brown algae directly enhance insulin secretion, prevent the formation of amyloid plaques, and decrease hyperglycemia in type 2 DM [53]. These reviews have several limitations including the lack of human clinical studies, focusing only on specific components of LJP, and targeting seaweeds other than LJP. There are various valid components of LJP (polysaccharides, phenolic compounds, or...
pigments), and the seaweed composition may vary according to algal species, degree of maturity, storage, and processing conditions after harvesting [54].

Atherosclerosis is a disease characterized by chronic inflammation of medium-and large-sized arteries and plaque formation in the intima. LJP inhibits atherothrombosis by (1) suppressing oxidative stress-related lipid mechanisms including the inhibition of LDL oxidation, the uptake of oxidized LDL, production of reactive oxygen species (ROS) and LOX-1, and enhancing the activities of antioxidant enzymes such as SOD and CAT; (2) reducing the secretion of inflammatory cytokines (e.g., IL-6, IL-1β, TNF-α, etc.) and macrophage-related chemokines; (3) interrupting the PI3K/Akt pathway; and (4) regulating the proliferation and migration of vascular smooth muscle cells. ROS plays an important role in LDL-C oxidation, which increases the expression of cell adhesion molecules including VCAM-1 and ICAM-1. They mediate the adhesion of leukocytes to the endothelial cells [55]. LOX-1 is one of the primary receptors of oxidized LDL, which facilitates oxidized LDL uptake and increases the expression of monocyte chemoattractant protein (MCP-1) and the apoptosis of endothelial cells. MCP-1 stimulates macrophage infiltration of the arterial wall during the early stages of atherogenesis [56,57]. The PI3K/Akt pathway thickens the arterial wall and induces plaque formation and vascular smooth muscle cell (VSMC) proliferation and contractility [58,59]. VSMC are a significant source of plaque cells; thus, they are implicated mechanistically at all stages of atherosclerosis [60]. Although more research is needed to understand the precise role of LJP in anti-atherosclerosis mechanisms, LJP may potentially treat atherosclerosis via antioxidant and anti-inflammatory mechanisms.

The mechanism of LJP in diabetes in this review can be summarized as follows: (1) the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications; (2) a therapeutic target in obesity and type 2 DM is lowering FFA; and (3) antioxidants reduce free radicals. α-Glucosidase, a carbohydrate-hydrolyzing enzyme, is generally competitively inhibited by α-glucosidase inhibitors, leading to delayed glucose absorption in the small intestine and ultimately controlling postprandial hyperglycemia [61]. This mechanism is a modern therapeutic approach for patients with type 2 DM (e.g., miglitol, acarbose, and voglibose are commercially available drugs). However, regular administration of these drugs results in various adverse events such as stomach pain and diarrhea [62]. Hence, LJP may be considered as a potent α-glucosidase inhibitor to reduce diabetic complications due to its immense efficacy in modulating postprandial hyperglycemia and minimal side effects. The relationship between glucose and FFA metabolism is well-described in the 'Randle theory', which demonstrates that FFA competes with glucose as an energy substrate in the muscle and adipose tissue; therefore, it inhibits the insulin signaling pathway, leading to insulin resistance in the skeletal muscle and liver [63]. Chronically elevated FFA levels also have a deleterious effect on the pancreas, which may increase the formation of NO, inducing β-cell apoptosis [64]. Natural compounds from LJP, polysaccharides, may be a therapeutic option for type 2 DM and obesity by reducing elevated FFA levels or insulin resistance. In addition, half of the studies in this review (5 out of 10) reported on the antioxidant defense mechanisms of LJP with oxidative stress biomarkers including GSH levels, GSH-Px, MDA, NO concentration, ROS, and SOD. Abnormally high levels of free radicals and subsequent activation of the transcription factor (NF-κB) have been linked to the enhancement of NO production, leading to islet β-cell damage and the development of late diabetic complications [65]. Interestingly, LJP lowered NO production (in islet cells of rats) and increased NO bioavailability (in endothelial cells of rat hindlimbs) to achieve the homeostasis of NO concentration [24,25]. Excessive NO production is involved in the development of pro-inflammatory reactions, tissue damage, and organ dysfunction [66,67]. Endothelium-derived NO is one of the most potent endogenous vasoprotective agents in normal vascular physiology because of its anti-inflammatory, anti-proliferative, and antithrombotic properties [68,69].

The anti-obesity mechanism of LJP in this review can be summarized as follows: (1) an increase in AMPK; (2) a decrease in ACC; and (3) a decrease in TNF-α and IL-6. Obesity is caused by a chronic imbalance in energy output and intake when excess energy
accumulates in white adipose tissue instead of brown adipose tissue, which is difficult to prevent and cure in humans [70]. Notably, obesity is the leading cause of type 2 DM and insulin resistance [71]. AMPK is a key factor that regulates energy homeostasis and is used to target obesity-related drugs [72]. For example, *Rhus chinensis* Mill (Wu et al., 2021), *Chrysanthemum morifolium* flower [73], and sulforaphane in broccoli [74], etc. have shown anti-obesity effects through the regulation of AMPK. Since AMPK is a crucial molecule in obesity, most studies in this review showed an elevated expression of AMPK, decreasing p-SREBP1-c, p-ACC, CPT-1, and TNF-α. Fatty acids play an essential role in humans by acting as signaling molecules and structural components [75]. However, aberrant upregulation of fatty acid production can cause obesity. Inhibiting the core enzymes involved in fatty acid synthesis including ACC and FAS could be an attractive therapeutic target for obesity [76]. Inflammation is one of the critical processes associated with obesity, and the expression of TNF-α, an essential pro-inflammatory cytokine, is elevated in the adipose tissue of several experimental models of obesity [77,78]. LJP significantly decreased the expression of p-ACC and TNF-α in the studies reviewed.

The bioavailability of fucoidan and iodine extracted from LJP was also studied. Zhao et al. compared two types of fucoidan regarding their bioavailability, medium molecular weight (MMW) fucoidan, and LMWF in rats. They found that oral administration of LMWF resulted in better absorption and antithrombotic effects than MMW fucoidan. High-performance liquid chromatography (HPLC) analysis of fucoidan in the plasma and urine samples showed that 200, 400, and 800 mg/kg LMWF and 800 mg/kg MMW fucoidan significantly increased the plasma and urine levels of fucose, suggesting higher bioavailability of LMWF compared to that of MMW fucoidan [79]. Sun et al. compared various pretreatment methods for the bioavailability of iodine in LJP in vitro based on the ratio of absorbed and added iodine by/to cells. They found that boiled LJP had a higher bioavailability than steamed and soaked LJP. However, further studies are required [80]. In addition to fucoidan and iodine, alginates, polyphenols, and polysaccharides as bioactive nutritional compounds extracted from LJP have been evaluated as solutions for the treatment and prevention of Met-related diseases [81]. In this review, alginates, polyphenols and polysaccharides have been reported to possess anti-diabetic [3,10,19,24,33], anti-obesity [29–32,38], antioxidant [15,34,37], anti-inflammatory [37,38], and hypolipidemic [15,33,34,37] effect.

Although the interaction of LJP with other drugs or herbs has rarely been studied, fucoidan, a sulfated polysaccharide extracted from brown algae, has been studied in combination with other drugs, primarily chemotherapeutic drugs, in cancer patients. For example, in this study, fucoidan (extracted from *Cladosiphon okamuranus*) was administered with chemotherapeutic drugs (oxaliplatin plus 5-fluorouracil/leucovorin or irinotecan plus 5-fluorouracil/leucovorin). It showed potential anticancer effects against recurrent colorectal cancer by lowering the cytotoxic effects of chemotherapy drugs in patients with nausea, vomiting, stomatitis, diarrhea, and liver dysfunction [82]. In addition, fucoidan derived from *Undaria pinnatifida* was administered to breast cancer patients undergoing hormonal therapies using letrozole and tamoxifen, and the daily administration of 1 g of fucoidan for 3 weeks did not change the plasma levels of letrozole and tamoxifen or reports of toxicity [83].

The recent findings in this review support the idea of the effect of LJP on MetS. However, this study had several limitations. Due to the small number of studies and the diverse outcomes in the included studies, we could not perform a meta-analysis of the LJP clinical trials. Despite growing evidence from in vitro and in vivo studies, there is no substantial evidence to support the effect of LJP in humans. A detailed investigation of the mechanism is lacking including those of the individual studies in this review. For example, indices related to lipogenic and lipolytic metabolism, 3T3-L1 cells or PPAR-γ, and the activity of enzymes involved in hepatic glucose metabolism including glucose-6-phosphatase (G-6-Pase) and G-6-phosphate dehydrogenase (G-6-PDH) have not been investigated as yet. There is also a need to establish an adequate MetS model. Most studies
on diabetes in this review (8 out of 10) used STZ or alloxan as the diabetogenic chemicals. STZ or alloxan destroys pancreatic beta cells to induce diabetes in an experimental model. Therefore, they may not well-represent type 2 DM [84]. Future studies on the toxicity of the long-term administration of LJP should be conducted.

In this review, we summarized the available evidence on the effects and mechanisms of LJP on MetS: obesity, diabetes, atherosclerosis, and hyperlipidemia (Figure 5). We found significant evidence of the antioxidant, hypoglycemic, and hypolipidemic effects of LJP in various animal models of MetS as well as in a few clinical trials. On the other hand, the safety, active components, extraction methods for better absorption, and the dose level of LJP should be tested both in vivo and in vitro. Based on this evidence, we suggest large clinical trials to demonstrate the effects of LJP in combination with conventional drugs.

![Figure 5. A schematic overview of the main mechanisms of LJP against atherosclerosis, obesity, and diabetes.](image)

**Figure 5.** A schematic overview of the main mechanisms of LJP against atherosclerosis, obesity, and diabetes. LJP inhibits atherothrombosis by interrupting oxidative stress-related lipid peroxidation, the PI3K/Akt signaling pathway, inflammatory and macrophage-related cytokines, and the proliferation and migration of VSMC. LJP exhibits the anti-obesity effect through the upregulation of P-AMPK. Subsequently, it inhibits ACC, SREBP-1c, and TNF-α, which results in decreased FA synthesis. LJP has the potential to play a role as the anti-diabetic agent through the inhibition of the mobilization of FFA, PKC, oxidative stress, and α-glucosidases. LJP may increase glucose uptake and responsiveness to insulin in the muscle and recover the pancreatic islet cell secreting function, resulting in the regulation of blood sugar level and insulin resistance. ACC1: acetyl-CoA carboxylase; CAT: catalase; FFA: free fatty acids; IL: interleukin; LCAT: lecithin cholesterol acyltransferase; LJP: *Laminaria japonica*; LOX-1: lectin-like oxidized low-density lipoprotein receptor-1; LPL: lipoprotein lipase; PI3K/Akt: phosphoinositide 3-kinase/protein kinase B; PKC: protein kinase C; ROS: reactive oxygen species; SOD: superoxide dismutase; TNF-α: tumor necrosis factor-α.

**Supplementary Materials:** The following are available online at www.mdpi.com/xxx/s1, Table S1: Database search strategies.

**Author Contributions:** I.-S.L.: Conceptualization, Formal analysis, Writing—original draft, Writing—review & editing, Funding acquisition. S.-J.K.: Conceptualization, Writing—review & editing, Funding acquisition. Y.N.L.: Methodology, Data curation, Writing—original draft. G.L.: Methodology, Data curation. M.H.R.: Visualization, Writing—original draft. B.K.: Conceptualization, Formal analysis, Writing—review & editing, Supervision. All authors have read and agreed to the published version of the manuscript.
Funding: This research was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2022R1C1C1004937), the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1I1A2066886), and a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (Nos. 2020R1A5A2019413, 2020R1A4A1018598).

Institutional Review Board Statement: Not available.

Data Availability Statement: Not available.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kim, B.; Lee, I.S.; Ko, S.J. The efficacy and safety of laminaria japonica for metabolic syndrome: A protocol for systematic review. *Medicine* **2022**, *101*, e28892. [CrossRef] [PubMed]

2. Huang, C.; Chen, X.; Wei, C.; Wang, H.; Gao, D. Deep eutectic solvents as active pharmaceutical ingredient delivery systems in the treatment of metabolic related diseases. *Front. Pharmacol.* **2021**, *12*, 794939. [CrossRef] [PubMed]

3. Jia, X.; Yang, J.; Wang, Z.; Liu, R.; Xie, R. Polysaccharides from laminaria japonica show hypoglycemic and hypolipidemic activities in mice with experimentally induced diabetes. *Exp. Biol. Med.* **2014**, *239*, 1663–1670. [CrossRef] [PubMed]

4. Hoffman, D.J.; Powell, T.L.; Barrett, E.S.; Hardy, D.B. Developmental origins of metabolic disease. *Physiol. Rev.* **2021**, *101*, 739–795. [CrossRef]

5. Naghipour, M.; Joukar, F.; Nikbakht, H.-A.; Hassanipour, S.; Asgharnejad, M.; Arab-Zozani, M.; Mansour-Ghanaei, F. High prevalence of metabolic syndrome and its related demographic factors in north of Iran: Results from the persian guilan cohort study. *Int. J. Endocrinol.* **2021**, *2021*, 8862456. [CrossRef]

6. Dahlén, A.D.; Dashi, G.; Maslov, I.; Attwood, M.M.; Jonsson, J.; Trukhan, V.; Schütt, H.B. Trends in antidiabetic drug discovery: Fda approved drugs, new drugs in clinical trials and global sales. *Front. Pharmacol.* **2021**, *12*, 807548. [CrossRef]

7. Ritter, K.; Buning, C.; Halland, N.; Poverlein, C.; Schwink, L. G protein-coupled receptor 119 (gpr119) agonists for the treatment of diabetes: Recent progress and prevailing challenges. *J. Med. Chem.* **2016**, *59*, 3579–3592. [CrossRef]

8. Kang, S.Y.; Kim, E.; Kang, I.; Lee, M.; Lee, Y. Anti-diabetic effects and anti-inflammatory effects of laminaria japonica and hizikia fusiforme in skeletal muscle: In vitro and in vivo model. *Nutrients* **2018**, *10*, 491. [CrossRef]

9. Shirotsuki, M.; Koyama, T. Laminaria japonica as a food for the prevention of obesity and diabetes. *Adv. Food Nutr. Res.* **2011**, *64*, 199–212.

10. Wang, X.; Zhang, L.; Qin, L.; Wang, Y.; Chen, F.; Qu, C.; Miao, J. Physicochemical properties of the soluble dietary fiber from laminaria japonica and its role in the regulation of type 2 diabetes mice. *Nutrients* **2022**, *14*, 329. [CrossRef]

11. Zhang, L.; Chen, Q.; Li, L.; Kwong, J.S.; Jia, P.; Zhao, P.; Wang, W.; Zhou, X.; Zhang, M.; Sun, X. Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: A systematic review and meta-analysis. *Sci. Rep.* **2016**, *6*, 32649. [CrossRef]

12. Luan, F.; Zou, J.; Rao, Z.; Ji, Y.; Lei, Z.; Peng, L.; Yang, Y.; He, X.; Zeng, N. Polysaccharides from laminaria japonica: An insight into the current research on structural features and biological properties. *Food Funct.* **2021**, *12*, 4254–4283. [CrossRef]

13. Oh, J.-H.; Kim, J.; Lee, Y. Anti-inflammatory and anti-diabetic effects of brown seaweeds in high-fat diet-induced obese mice. *Nutr. Res. Pract.* **2016**, *10*, 42–48. [CrossRef]

14. Yao, Y.; Xiang, H.; You, L.; Cui, C.; Sun-Waterhouse, D.; Zhao, M. Hypolipidaemic and antioxidant capacities of polysaccharides obtained from laminaria japonica by different extraction media in diet-induced mouse model. *Int. J. Food Sci. Technol.* **2017**, *52*, 2274–2281. [CrossRef]

15. Xie, L.; Chen, M.-H.; Li, J.; Yang, X.-M.; Huang, Q.-J. Antithrombotic effect of a polysaccharide fraction from laminaria japonica from the south china sea. *Phytother. Res.* **2011**, *25*, 1362–1366. [CrossRef]

16. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The prisma 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* **2021**, *372*, n71. [CrossRef]

17. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. *BMJ* **2019**, *366*, 14896. [CrossRef]

18. Li, X.; Yu, Z.; Long, S.; Guo, Y.; Duan, D. Hypoglycemic effect of laminaria japonica polysaccharide in a type 2 diabetes mellitus mouse model. *ISRN Endocrinol.* **2012**, *2012*, 507462. [CrossRef]

19. Bu, T.; Liu, M.; Zheng, L.; Guo, Y.; Lin, X. A-glucosidase inhibition and the in vivo hypoglycemic effect of butyl-isobutyl-phthalate derived from the laminaria japonica rhizoid. *Phytother. Res.* **2010**, *24*, 1588–1591. [CrossRef]

20. Jin, D.Q.; Li, G.; Kim, J.S.; Yong, C.S.; Kim, J.A.; Huh, K. Preventive effects of laminaria japonica aqueous extract on the oxidative stress and xanthine oxidase activity in streptozotocin-induced diabetic rat liver. *Biol. Pharm. Bull.* **2004**, *27*, 1037–1040. [CrossRef]

21. Liang, Z.; Zheng, Y.; Wang, J.; Zhang, Q.; Ren, S.; Liu, T.; Wang, Z.; Luo, D. Low molecular weight fucoidan ameliorates streptozotocin-induced hyper-responsiveness of aortic smooth muscles in type 1 diabetes rats. *J. Ethnopharmacol.* **2016**, *191*, 341–349. [CrossRef]
22. Park, M.Y.; Kim, E.; Kim, M.S.; Kim, K.H.; Kim, H.A. Dietary supplementation of sea tangle (Laminaria japonica) improves blood glucose and lipid metabolism in the streptozotocin-induced diabetic rats. Food Sci. Biotechnol. 2009, 18, 712–716.

23. Xu, J.; Wang, Y.; Wang, Z.; Guo, L.; Li, X. Fucoidan mitigated diabetic nephropathy through the downregulation of pke and modulation of NF-kB signaling pathway: In vitro and in vivo investigations. Phytother. Res. 2021, 35, 2133–2144. [CrossRef] [PubMed]

24. Long, S.H.; Yu, Z.Q.; Shuai, L.; Guo, Y.L.; Duan, D.L.; Xu, X.Y.; Li, X.D. The hypoglycemic effect of the kelp on diabetes mellitus model induced by alloxan in rats. Int. J. Mol. Sci. 2012, 13, 3354–3365. [CrossRef] [PubMed]

25. Wang, Z.; Liu, T.; Chen, X.; You, H.; Zhang, Q.; Xue, J.; Zheng, Y.; Luo, D. Low molecular weight fucoidan ameliorates hindlimb ischemic injury in type 2 diabetic rats. J. Ethnopharmacol. 2018, 210, 434–442. [CrossRef] [PubMed]

26. Shang, Q.; Song, G.; Zhang, M.; Shi, J.; Xu, C.; Hao, J.; Li, G.; Yu, G. Dietary fucoidan improves metabolic syndrome in association with increased akkermansia population in the gut microbiota of high-fat diet-fed mice. J. Funct. Foods 2017, 28, 138–146. [CrossRef]

27. Jang, W.S.; Choung, S.Y. Antiobesity effects of the ethanol extract of laminaria japonica are shown in high-fat-diet-induced obese rat. Evid.-Based Complement. Altern. Med. 2013, 2013, 492807.

28. Zhang, Y.; Zhao, N.; Yang, L.; Hong, Z.; Cai, B.; Le, Q.; Yang, T.; Shi, L.; He, J.; Cui, C.-B. Insoluble dietary fiber derived from brown seaweed laminaria japonica ameliorate obesity-related features via modulating gut microbiota dysbiosis in high-fat diet–fed mice. Food Funct. 2021, 12, 587–601. [CrossRef]

29. Li, N.; Fu, X.; Xiao, M.; Wei, X.; Yang, M.; Liu, Z.; Mou, H. Enzymatic preparation of a low-molecular-weight polysaccharide rich in uronic acid from the seaweed laminaria japonica and evaluation of its hypolipidemic effect in mice. Food Funct. 2020, 11, 2395–2405. [CrossRef]

30. Duan, M.; Sun, X.; Ma, N.; Liu, Y.; Luo, T.; Song, S.; Ai, C. Polysaccharides from laminaria japonica alleviated metabolic syndrome in babt/c mice by normalizing the gut microbiota. Int. J. Biol. Macromol. 2019, 121, 996–1004. [CrossRef]

31. Han, A.R.; Kim, J.H.; Kim, E.; Cui, J.; Chai, I.S.; Zhang, G.; Lee, Y. Hypotriglyceridemic effects of brown seaweed consumption via regulation of bile acid excretion and hepatic lipogenesis in high fat diet-induced obese mice. Nutr. Res. Pract. 2020, 14, 580–592. [CrossRef]

32. Li, Q.M.; Zha, X.Q.; Zhang, W.N.; Liu, J.; Pan, L.H.; Luo, J.P. Laminaria japonica polysaccharide prevents high-fat-diet-induced insulin resistance in mice via regulating gut microbiota. Food Funct. 2021, 12, 5260–5273. [CrossRef] [PubMed]

33. Peng, F.H.; Zha, X.Q.; Cui, S.H.; Asghar, M.N.; Pan, L.H.; Wang, J.H.; Luo, J.P. Purification, structure features and anti-atherosclerosis activity of a laminaria japonica polysaccharide. Int. J. Biol. Macromol. 2015, 81, 926–935. [CrossRef] [PubMed]

34. Huang, L.; Wen, K.; Gao, X.; Liu, Y. Hypolipidemic effect of fucoidan from laminaria japonica in hyperlipidemic rats. Pharm. Biol. 2010, 48, 422–426. [CrossRef] [PubMed]

35. Zha, X.Q.; Xiao, J.J.; Zhang, H.-N.; Wang, J.-H.; Pan, L.-H.; Yang, X.-F.; Le, Q.; Yang, T.; Shi, L.; He, J.; Cui, C.-B. Insoluble dietary fiber derived from brown seaweed laminaria japonica ameliorate obesity-related features via modulating gut microbiota dysbiosis in high-fat diet–fed mice. Food Funct. 2021, 12, 587–601. [CrossRef] [PubMed]

36. Zha, X.Q.; Xiao, J.J.; Zhang, H.-N.; Wang, J.-H.; Pan, L.-H.; Yang, X.-F.; Le, Q.; Yang, T.; Shi, L.; He, J.; Cui, C.-B. Insoluble dietary fiber derived from brown seaweed laminaria japonica ameliorate obesity-related features via modulating gut microbiota dysbiosis in high-fat diet–fed mice. Food Funct. 2021, 12, 587–601. [CrossRef] [PubMed]

37. Wang, X.; Pei, L.; Liu, H.; Qv, K.; Xian, W.; Liu, J.; Zhang, G. Fucoidan attenuates atherosclerosis in ldlr−/− mice through inhibition of inflammation and oxidative stress. Int. J. Clin. Exp. Pathol. 2016, 9, 6896–6904.

38. Zha, X.Q.; Zhang, W.N.; Peng, F.H.; Xue, L.; Liu, J.; Luo, J.P. Alleviating vidl overproduction is an important mechanism for laminaria japonica polysaccharide to inhibit atherosclerosis in ldlr−/− mice with diet-induced insulin resistance. Mol. Nutr. Food Res. 2017, 61, 1600456. [CrossRef] [PubMed]

39. Zhang, Q.; Fan, X.Y.; Gao, W.L.; Cao, Y.J.; Lin, Y.C.; Cheng, W.J.; Chen, L.J.; Rao, P.F.; Ni, L.; Lv, X.C. The protective mechanisms of macroalgae laminaria japonica consumption against lipid metabolism disorders in high-fat diet-induced hyperlipidemic rats. Food Funct. 2020, 11, 3256–3270. [CrossRef]

40. Zhang, Q.; Fan, X.Y.; Gao, W.L.; Cao, Y.J.; Zhang, T.-T.; Cheng, W.J.; Chen, L.J.; Lv, X.C.; Ni, L.; Rao, P.F.; Liang, P. The beneficial effects of lactobacillus brevis fzu0713-fermented laminaria japonica on lipid metabolism and intestinal microbiota in hyperlipidemic rats fed with a high-fat diet. Food Funct. 2021, 12, 7145–7160. [CrossRef]

41. Liu, Y.; Zhang, D.; Liu, G.-M.; Chen, Q.; Lu, Z. Ameliorative effect of dieckol-enriched extraction from laminaria japonica on hepatic steatosis induced by a high-fat diet via β-oxidation pathway in icr mice. J. Funct. Foods 2019, 58, 44–55. [CrossRef]

42. You, J.S.; Sung, M.J.; Chang, K.J. Evaluation of 8-week body weight control program including sea tangle (Laminaria japonica) supplementation in korean female college students. Nutr. Res. Pract. 2009, 3, 307–314. [CrossRef] [PubMed]

43. Nishiumi, S.; Izumi, Y.; Kobayashi, T.; Yoshida, M.J.F.S.; Research, T. A pilot study: Effects of kombu intake on lifestyle-related diseases—possibility that kombu intake is effective in individuals with abnormally high serum triglyceride levels. Food Sci. Technol. Res. 2019, 25, 827–834. [CrossRef]

44. Nishiumi, S.; Izumi, Y.; Kobayashi, T.; Yoshida, M. Possible involvement of lipids in the effectiveness of kombu in individuals with abnormally high serum triglyceride levels. J. Nutr. Sci. Vitaminol. 2020, 66, 185–190. [CrossRef]
46. Aoë, S.; Yamanaka, C.; Ohtoshi, H.; Nakamura, F.; Fujiiwara, S. Effects of daily kelp (Laminaria japonica) intake on body composition, serum lipid levels, and thyroid hormone levels in healthy Japanese adults: A randomized, double-blind study. *Mar. Drugs* **2021**, *19*, 352. [CrossRef] [PubMed]

47. Kang, Y.M.; Lee, B.J.; Kim, J.I.; Nam, B.H.; Cha, J.Y.; Kim, Y.M.; Ahn, C.B.; Choi, J.S.; Choi, I.S.; Je, J.Y. Antioxidant effects of fermented sea tangle (laminaria japonica) by lactobacillus brevis bj20 in individuals with high level of gamma-gt: A randomized, double-blind, and placebo-controlled clinical study. *Food Chem. Toxicol.* **2012**, *50*, 1166–1169. [CrossRef]

48. Ko, S.J.; Kim, J.; Han, G.; Kim, S.K.; Kim, H.G.; Yeo, I.; Ryu, B.; Park, J.W. Laminaria japonica combined with probiotics improves intestinal microflora: A randomized clinical trial. *J. Med. Food* **2014**, *17*, 76–82. [CrossRef]

49. Saklayen, M.G.J. C.h.r. The global epidemic of the metabolic syndrome. *Curr. Hypertens. Rep.* **2018**, *20*, 12. [CrossRef]

50. Choi, W.-c.; Reid, S.N.; Ryu, J.-k.; Kim, Y.; Jo, Y.-H.; Jeon, B.H. A. Effects of γ-aminobutyric acid-enriched fermented sea tangle (laminaria japonica) on brain derived neurotrophic factor-related muscle growth and lipolysis in middle aged women. *Algae* **2016**, *31*, 175–187. [CrossRef]

51. D’Orazio, N.; Gemello, E.; Gammon, M. A.; de Girolamo, M.; Ficoneri, C.; Riccioni, G. Fucoxanthin: A treasure from the sea. *Mar. Drugs* **2012**, *10*, 604–616. [CrossRef] [PubMed]

52. Gabbia, D.; De Martin, S. Brown seaweeds for the management of metabolic syndrome and associated diseases. *Molecules* **2020**, *25*, 4182. [CrossRef] [PubMed]

53. Popović-Djordjević, J.B.; Katanić Stanković, J.S.; Mihailović, V.; Pereira, A.G.; Garcia-Oliveira, P.; Prieto, M.A.; Simal-Gandara, J. Algae as a source of bioactive compounds to prevent the development of type 2 diabetes mellitus. *Curr. Med. Chem.* **2021**, *28*, 4592–4615. [CrossRef] [PubMed]

54. Gupta, S.; Abu-Ghannam, N. Bioactive potential and possible health effects of edible brown seaweeds. *Trends Food Sci. Technol.* **2011**, *22*, 315–326. [CrossRef]

55. Kattoor, A.J.; Pothineni, N.V.K.; Palagiri, D.; Mehta, J.L. Oxidative stress in atherosclerosis. *Curr. Atheroscler. Rep.* **2017**, *19*, 42. [CrossRef]

56. Li, D.; Mehta, J.L. Antisense to lox-1 inhibits oxidized ldl-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. *Circulation* **2000**, *101*, 2889–2895. [CrossRef]

57. Papadopoulou, C.; Corrigall, V.; Taylor, P.R.; Poston, R.N. The role of the chemokines mcp-1, gro-alpha, il-8 and their receptors in the adhesion of monocyte cells to human atherosclerotic plaques. *Cytokine* **2008**, *43*, 181–186. [CrossRef]

58. Zhao, Y.; Qian, Y.; Sun, Z.; Shen, X.; Cai, Y.; Li, L.; Wang, Z. Role of pi3k in the progression and regression of atherosclerosis. *Front. Pharmacol.* **2021**, *12*, 632378. [CrossRef]

59. Bonetti, J.; Corti, A.; Lerouge, L.; Gaucher, C. Phenotypic modulation of macrophages and vascular smooth muscle cells in atherosclerosis-nitro-redox interconnections. *Antioxidants* **2021**, *10*, 516. [CrossRef]

60. Basatemur, G.L.; Jorgensen, H.F.; Clarke, M.C.H.; Bennett, M.R.; Mallat, Z. Vascular smooth muscle cells in atherosclerosis-nitro-redox interconnections. *Antioxidants* **2021**, *10*, 516. [CrossRef]

61. Kumar, S.; Narwal, S.; Kumar, V.; Prakash, O. A-glucosidase inhibitors from plants: A natural approach to treat diabetes. *Pharmacogn. Rev.* **2011**, *5*, 19–29. [CrossRef] [PubMed]

62. Hossain, U.; Das, A.K.; Ghosh, S.; Sil, P.C. An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications. *Food Chem. Toxicol.* **2020**, *145*, 111738. [CrossRef]

63. Boden, G.; Shulman, G.I. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. *Eur. J. Clin. Investig.* **2002**, *32* (Suppl. S3), 13–23. [CrossRef]

64. Unger, R.H.; Zhou, Y.T. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. *Diabetes* **2001**, *50* (Suppl. 5), S18–S21. [CrossRef]

65. Maritim, A.C.; Sanders, R.A.; Watkins, J.B., 3rd. Diabetes, oxidative stress, and antioxidants: A review. *J. Biochem. Mol. Toxicol.* **2003**, *17*, 24–38. [CrossRef] [PubMed]

66. Rochette, L.; Zeller, M.; Cottin, Y.; Vergely, C. Diabetes, oxidative stress and therapeutic strategies. *Biochim. Biophys. Acta* **2014**, *1840*, 2709–2729. [CrossRef] [PubMed]

67. Guo, H.; Zhang, Q.; Yuan, H.; Zhou, L.; Li, F.F.; Wang, S.M.; Shi, G.; Wang, M. Nitric oxide mediates inflammation in type ii diabetes mellitus through the pparγ/enos signaling pathway. *PPAR Res.* **2020**, 8889612. [CrossRef]

68. Luiking, Y.C.; Engelen, M.P.; Deutz, N.E. Regulation of nitric oxide production in health and disease. *Curr. Opin. Clin. Nutr. Metab. Care* **2010**, *13*, 97–104. [CrossRef]

69. Yamagishi, S.; Matsu, T. Nitric oxide, a janus-faced therapeutic target for diabetic microangiopathy-friend or foe? *Pharmacol. Res.* **2011**, *64*, 187–194. [CrossRef]

70. Pollard, A.E.; Martins, L.; Muckett, P.J.; Khadayate, S.; Bornot, A.; Clausen, M.; Admyre, T.; Bjursell, M.; Fiadeiro, R.; Wilson, L.; et al. Ampk activation protects against diet-induced obesity through ucpcp-independent thermogenesis in subcutaneous white adipose tissue. *Nat. Metab.* **2019**, *1*, 340–349. [CrossRef]

71. Wondmkun, Y.T. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. *Diabetes Metab. Syndr. Obes.* **2020**, *13*, 3611–3616. [CrossRef] [PubMed]

72. Kola, B.; Grossman, A.B.; Korbonits, M. The role of amp-activated protein kinase in obesity. *Front. Horm. Res.* **2008**, *36*, 198–211. [PubMed]
73. Wu, Z.; Ma, Q.; Cai, S.; Sun, Y.; Zhang, Y.; Yi, J. Rhus chinensis mill. Fruits ameliorate hepatic glycolipid metabolism disorder in rats induced by high fat/high sugar diet. *Nutrients* 2021, 13, 4480. [CrossRef] [PubMed]

74. Ranaweera, S.S.; Natraj, P.; Rajan, P.; Dayarathne, L.A.; Mihindukulasooriya, S.P.; Dinh, D.T.T.; Jee, Y.; Han, C.H. Anti-obesity effect of sulforaphane in broccoli leaf extract on 3t3-l1 adipocytes and ob/ob mice. *J. Nutr. Biochem.* 2022, 100, 108885. [CrossRef]

75. Batchuluun, B.; Pinkosky, S.L.; Steinberg, G.R. Lipogenesis inhibitors: Therapeutic opportunities and challenges. *Nat. Rev. Drug Discov.* 2022, 21, 283–305. [CrossRef]

76. Choe, S.Y.; Seo, Y.; Bang, C.Y.; Woo, S.H.; Kang, M. Protective effects of gymnaster koraiensis extract on high fat diet-induced fatty liver in mice. *Adv. Tradit. Med.* 2021, 21, 361–369. [CrossRef] [PubMed]

77. Hotamisligil, G.S.; Spiegelman, B.M. Tumor necrosis factor alpha: A key component of the obesity-diabetes link. *Diabetes* 1994, 43, 1271–1278. [CrossRef]

78. Zelová, H.; Hošek, J. Tnf-α signalling and inflammation: Interactions between old acquaintances. *Inflamm. Res.* 2013, 62, 641–651. [CrossRef]

79. Zhao, X.; Guo, F.; Hu, J.; Zhang, L.; Xue, C.; Zhang, Z.; Li, B. Antithrombotic activity of oral administered low molecular weight fucoidan from laminaria japonica. *Thromb. Res.* 2016, 144, 46–52. [CrossRef]

80. Sun, N.; Sun, B.; Li, C.; Zhang, J.; Yang, W. Effects of different pretreatment methods and dietary factors on the form and bioavailability of iodine in laminaria japonica. *J. Aquat. Food Prod. Technol.* 2022, 31, 154–169. [CrossRef]

81. Wijesinghe, W.A.J.P.; Jeon, Y.-J. Biological activities and potential cosmeceutical applications of bioactive components from brown seaweeds: A review. *Phytochem. Rev.* 2011, 10, 431–443. [CrossRef]

82. Ikeguchi, M.; Yamamoto, M.; Arai, Y.; Maeta, Y.; Ashida, K.; Katano, K.; Miki, Y.; Kimura, T. Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. *Oncol. Lett.* 2011, 2, 319–322. [CrossRef] [PubMed]

83. Tocaciu, S.; Oliver, L.J.; Lowenthal, R.M.; Peterson, G.M.; Patel, R.; Shastri, M.; McGuinness, G.; Olesen, I.; Fitton, J.H. The effect of undaria pinnatifida fucoidan on the pharmacokinetics of letrozole and tamoxifen in patients with breast cancer. *Integr. Cancer Ther.* 2018, 17, 99–105. [CrossRef] [PubMed]

84. Lenzen, S. The mechanisms of alloxan- and streptozotocin-induced diabetes. *Diabetologia* 2008, 51, 216–226. [CrossRef] [PubMed]